痛风患者的用药依从性:系统综述与Meta分析
该系统综述与Meta分析检索PubMed、Embase、CINAHL和PsycINFO中痛风患者降尿酸治疗(ULT)依从性研究,合并13项研究显示依从患者比例为46%(95%CI:41-51),美国研究为45%(n=8),其他国家为48%(n=5);非持续性(n=6)范围为54%至87%;较强证据支持年龄较大、合并症较多及存在糖尿病或高血压与依从性正相关。
要点
- 痛风患者ULT依从性差,合并依从患者比例为46%(95%CI:41-51)。
- 非持续性(治疗间隙≥30天)在6项研究中范围为54%至87%。
- 年龄较大、合并症较多及糖尿病或高血压与依从性正相关有较强证据。
核心结论
- 痛风患者对降尿酸治疗的用药依从性差,需要更好地了解依从性差的原因和后果。
研究设计与样本
- 系统文献检索PubMed、Embase、CINAHL和PsycINFO中痛风患者ULT依从性研究,共纳入24项研究。
- 采用随机效应模型对报告依从至少80%处方药物或时间比例的研究进行Meta分析。
- 探索异质性来源包括地理区域和依从性测量方法,并对MEMS/药片计数或患者报告、治疗间隙≥30天(非持续性)及依从相关因素进行叙述性总结。
主要发现
- 24项研究中,16项使用处方/索赔数据评估依从性,2项使用MEMS或药片计数,6项使用患者报告数据。
- 合并依从患者比例(n=13)为46%(95%CI:41-51);美国研究(n=8)为45%,其他国家研究(n=5)为48%。
- MEMS/药片计数和患者报告评估的依从性远高于使用处方/索赔数据的研究。
- 非持续性(n=6)范围为54%至87%。
- 18项研究调查了依从相关因素,较强证据支持年龄较大、合并症较多及存在糖尿病或高血压与依从性正相关。
关键数值与推荐
- 依从定义为至少80%处方药物或时间比例。
- 非持续性定义为治疗间隙≥30天。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the management of chronic gout, a large proportion of patients need long-term management with urate lowering therapy (ULT). This study reviews medication adherence to ULT and summarizes factors associated with adherence. METHODS: We performed a systematic literature search for studies on adherence to ULT among gout patients in PubMed, Embase, CINAHL, and PsycINFO. We conducted meta-analysis, with a random effect model, for the studies reporting the proportion of patients considered adherent to at least 80% of prescribed medication or time taken. We explored potential sources of heterogeneity, including geographic area and measure of adherence. Narrative summaries were made for data on adherence assessed/defined by Medication Event Monitoring System (MEMS)/pill-count or patient-reported, occurrence of a gap in therapy ≥30 days (non-persistence), and factors associated with adherence. RESULTS: Of the 24 studies, 16 assessed adherence using prescription/claims data, two by the MEMS or pill count, and six by patient-reported data. The pooled proportion of adherent patients (n = 13) was 46% (95% CI: 41-51); 45% across studies conducted in the USA (n = 8) and 48% in other countries (n = 5). Adherence assessed by MEMS/pill count and patient-reported was much higher than by studies using prescription/claims data. Non-persistence (n = 6) ranged from 54% to 87%. Factors associated with adherence were investigated in 18 studies. Strong evidence for a positive association with older age, more comorbidities, and the presence of diabetes or hypertension was found. CONCLUSION: Medication adherence to ULT among gout patients was poor. Better insight into reasons and consequences or poor adherence is needed.
引用
- Scheepers LEJM, van Onna M, Stehouwer CDA, et al. Medication adherence among patients with gout: A systematic review and meta-analysis. Semin Arthritis Rheum. 2017. PMID: 29198878. doi:10.1016/j.semarthrit.2017.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。